ESMO 2024: Eli Lilly brings the competition to Novartis with new results in mCRPC

On 15 September 15 2024 results for the Phase III SPLASH trial were presented at the European Society of Medical Oncology (ESMO) Congress 2024.

The trial compares Eli Lilly’s lutetium zadavotide guraxetan (177Lu-PNT2002) with the androgen receptor pathway inhibitors (ARPIs), Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga (abiraterone acetate), in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) positive for prostate-specific membrane antigen (PSMA) who have progressed on one line of ARPIs.